The weather is getting cooler, but biotech’s recovery is heating up. After a years-long wait-and-see game exhausted many ...

Sanofi is offloading its rare autoimmune disease medicine Enjaymo to an Italian pharmaceutical company for $825 million ...

Andrew Miller has quickly made his first move after the technology he invented, KarXT, secured an FDA approval last week. The ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

Eli Lilly’s blockbuster GLP-1 drug tirzepatide is finally back on track in the US after two years of intermittent shortages ...

WuXi AppTec and WuXi Biologics are reportedly looking to sell part of their operations that have struggled because of ...

The UK’s publicly funded healthcare system has proposed phasing its rollout of Eli Lilly’s weight loss treatment tirzepatide ...

The FDA's Center for Drug Evaluation and Research on Wednesday officially launched a new center of excellence to better ...

Relay Therapeutics is laying off 10% of its staff, or about 30 employees, in an additional round of job cuts after a smaller ...

Novo Nordisk and Eli Lilly, whose obesity drugs are some of the most in-demand drugs in the US, have drafted plans to avoid ...

Flagship Pioneering's roots in Singapore are growing less than a year after the biotech incubator first unveiled its ...

Kurma Partners has closed the first part of its latest biotech-focused fund, following a pair of M&A exits for drug ...